Misselijkheid en braken na chemotherapie in de dagelijkse praktijk: Uitkomstenonderzoek in negen algemene ziekenhuizen

Translated title of the contribution: Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study

Doranne L. Hilarius, Paul H. Kloeg, Elsken Van Der Wall, Joris J G Van Den Heuvel, Chad M. Gundy, Neil K. Aaronson

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Chemotherapy-induced nausea and vomiting (CINV) are major adverse effects of cancer chemotherapy. This study investigated: (1) the impact of CINV on patients' health-related quality of life (HRQL) in daily practice; (2) the association between patient characteristics, type of antiemetics and CINV; and (3) the role of CINV in physicians' decisions to modify antiemetic treatment. DESIGN AND METHODS : This prospective, multicenter study was conducted in 9 general hospitals In the Netherlands. During three consecutive chemotherapy cycles, patients used a diary to record episodes of nausea, vomiting and antiemetic use. For each cycle, these ratings were made one day prior to and six days after having received chemotherapy. The influence of CINV on patients' HRQL was evaluated with the Functional Living Index-Emesis (FLIE) questionnaire at day 6 of each treatment cycle. (Changes in) antiemetic use were recorded by the treating nurse. RESULTS: 277 patients were enrolled in the study. Acute and delayed nausea during the first treatment cycle was reported by 39% and 68% of the patients, respectively. The comparable figures for acute and delayed vomiting were 12% and 23%. Approximately one-third of the patients indicated that CINV had a substantial impact on their daily lives. Patients receiving treatment with moderately emetogenic chemotherapy containing anthracycline, reported more acute nausea than patients receiving highly emetogenic chemotherapy. Acute vomiting was associated significantly with change in (i.e., additional) antiemetic treatment. Delayed CINV did not influence antiemetic treatment. CONCLUSION: In daily clinical practice, acute CINV, but not delayed CINV, results in changes in antiemetic treatment. In view of the effects of not only acute but also delayed CINV on daily life, more attention should be paid to adjustment of anti-emetic treatment to cover CINV complaints later during the chemotherapy cycle.

Original languageDutch
Pages (from-to)168-176
Number of pages9
JournalPharmaceutisch Weekblad
Volume147
Issue number42
StatePublished - Oct 19 2012
Externally publishedYes

Fingerprint

Community Hospital
Nausea
Vomiting
Drug Therapy
Antiemetics
Therapeutics
Quality of Life
Anthracyclines
General Hospitals
Netherlands

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hilarius, D. L., Kloeg, P. H., Van Der Wall, E., Van Den Heuvel, J. J. G., Gundy, C. M., & Aaronson, N. K. (2012). Misselijkheid en braken na chemotherapie in de dagelijkse praktijk: Uitkomstenonderzoek in negen algemene ziekenhuizen. Pharmaceutisch Weekblad, 147(42), 168-176.

Misselijkheid en braken na chemotherapie in de dagelijkse praktijk : Uitkomstenonderzoek in negen algemene ziekenhuizen. / Hilarius, Doranne L.; Kloeg, Paul H.; Van Der Wall, Elsken; Van Den Heuvel, Joris J G; Gundy, Chad M.; Aaronson, Neil K.

In: Pharmaceutisch Weekblad, Vol. 147, No. 42, 19.10.2012, p. 168-176.

Research output: Contribution to journalArticle

Hilarius, DL, Kloeg, PH, Van Der Wall, E, Van Den Heuvel, JJG, Gundy, CM & Aaronson, NK 2012, 'Misselijkheid en braken na chemotherapie in de dagelijkse praktijk: Uitkomstenonderzoek in negen algemene ziekenhuizen', Pharmaceutisch Weekblad, vol. 147, no. 42, pp. 168-176.
Hilarius DL, Kloeg PH, Van Der Wall E, Van Den Heuvel JJG, Gundy CM, Aaronson NK. Misselijkheid en braken na chemotherapie in de dagelijkse praktijk: Uitkomstenonderzoek in negen algemene ziekenhuizen. Pharmaceutisch Weekblad. 2012 Oct 19;147(42):168-176.
Hilarius, Doranne L. ; Kloeg, Paul H. ; Van Der Wall, Elsken ; Van Den Heuvel, Joris J G ; Gundy, Chad M. ; Aaronson, Neil K. / Misselijkheid en braken na chemotherapie in de dagelijkse praktijk : Uitkomstenonderzoek in negen algemene ziekenhuizen. In: Pharmaceutisch Weekblad. 2012 ; Vol. 147, No. 42. pp. 168-176.
@article{297d93a3f10d45bfb9e0b62438e4061d,
title = "Misselijkheid en braken na chemotherapie in de dagelijkse praktijk: Uitkomstenonderzoek in negen algemene ziekenhuizen",
abstract = "OBJECTIVE: Chemotherapy-induced nausea and vomiting (CINV) are major adverse effects of cancer chemotherapy. This study investigated: (1) the impact of CINV on patients' health-related quality of life (HRQL) in daily practice; (2) the association between patient characteristics, type of antiemetics and CINV; and (3) the role of CINV in physicians' decisions to modify antiemetic treatment. DESIGN AND METHODS : This prospective, multicenter study was conducted in 9 general hospitals In the Netherlands. During three consecutive chemotherapy cycles, patients used a diary to record episodes of nausea, vomiting and antiemetic use. For each cycle, these ratings were made one day prior to and six days after having received chemotherapy. The influence of CINV on patients' HRQL was evaluated with the Functional Living Index-Emesis (FLIE) questionnaire at day 6 of each treatment cycle. (Changes in) antiemetic use were recorded by the treating nurse. RESULTS: 277 patients were enrolled in the study. Acute and delayed nausea during the first treatment cycle was reported by 39{\%} and 68{\%} of the patients, respectively. The comparable figures for acute and delayed vomiting were 12{\%} and 23{\%}. Approximately one-third of the patients indicated that CINV had a substantial impact on their daily lives. Patients receiving treatment with moderately emetogenic chemotherapy containing anthracycline, reported more acute nausea than patients receiving highly emetogenic chemotherapy. Acute vomiting was associated significantly with change in (i.e., additional) antiemetic treatment. Delayed CINV did not influence antiemetic treatment. CONCLUSION: In daily clinical practice, acute CINV, but not delayed CINV, results in changes in antiemetic treatment. In view of the effects of not only acute but also delayed CINV on daily life, more attention should be paid to adjustment of anti-emetic treatment to cover CINV complaints later during the chemotherapy cycle.",
author = "Hilarius, {Doranne L.} and Kloeg, {Paul H.} and {Van Der Wall}, Elsken and {Van Den Heuvel}, {Joris J G} and Gundy, {Chad M.} and Aaronson, {Neil K.}",
year = "2012",
month = "10",
day = "19",
language = "Dutch",
volume = "147",
pages = "168--176",
journal = "Pharmaceutisch Weekblad",
issn = "0031-6911",
publisher = "Kon. Ned. Mij. ter Bevordering der Pharmacie (KNMP)",
number = "42",

}

TY - JOUR

T1 - Misselijkheid en braken na chemotherapie in de dagelijkse praktijk

T2 - Uitkomstenonderzoek in negen algemene ziekenhuizen

AU - Hilarius, Doranne L.

AU - Kloeg, Paul H.

AU - Van Der Wall, Elsken

AU - Van Den Heuvel, Joris J G

AU - Gundy, Chad M.

AU - Aaronson, Neil K.

PY - 2012/10/19

Y1 - 2012/10/19

N2 - OBJECTIVE: Chemotherapy-induced nausea and vomiting (CINV) are major adverse effects of cancer chemotherapy. This study investigated: (1) the impact of CINV on patients' health-related quality of life (HRQL) in daily practice; (2) the association between patient characteristics, type of antiemetics and CINV; and (3) the role of CINV in physicians' decisions to modify antiemetic treatment. DESIGN AND METHODS : This prospective, multicenter study was conducted in 9 general hospitals In the Netherlands. During three consecutive chemotherapy cycles, patients used a diary to record episodes of nausea, vomiting and antiemetic use. For each cycle, these ratings were made one day prior to and six days after having received chemotherapy. The influence of CINV on patients' HRQL was evaluated with the Functional Living Index-Emesis (FLIE) questionnaire at day 6 of each treatment cycle. (Changes in) antiemetic use were recorded by the treating nurse. RESULTS: 277 patients were enrolled in the study. Acute and delayed nausea during the first treatment cycle was reported by 39% and 68% of the patients, respectively. The comparable figures for acute and delayed vomiting were 12% and 23%. Approximately one-third of the patients indicated that CINV had a substantial impact on their daily lives. Patients receiving treatment with moderately emetogenic chemotherapy containing anthracycline, reported more acute nausea than patients receiving highly emetogenic chemotherapy. Acute vomiting was associated significantly with change in (i.e., additional) antiemetic treatment. Delayed CINV did not influence antiemetic treatment. CONCLUSION: In daily clinical practice, acute CINV, but not delayed CINV, results in changes in antiemetic treatment. In view of the effects of not only acute but also delayed CINV on daily life, more attention should be paid to adjustment of anti-emetic treatment to cover CINV complaints later during the chemotherapy cycle.

AB - OBJECTIVE: Chemotherapy-induced nausea and vomiting (CINV) are major adverse effects of cancer chemotherapy. This study investigated: (1) the impact of CINV on patients' health-related quality of life (HRQL) in daily practice; (2) the association between patient characteristics, type of antiemetics and CINV; and (3) the role of CINV in physicians' decisions to modify antiemetic treatment. DESIGN AND METHODS : This prospective, multicenter study was conducted in 9 general hospitals In the Netherlands. During three consecutive chemotherapy cycles, patients used a diary to record episodes of nausea, vomiting and antiemetic use. For each cycle, these ratings were made one day prior to and six days after having received chemotherapy. The influence of CINV on patients' HRQL was evaluated with the Functional Living Index-Emesis (FLIE) questionnaire at day 6 of each treatment cycle. (Changes in) antiemetic use were recorded by the treating nurse. RESULTS: 277 patients were enrolled in the study. Acute and delayed nausea during the first treatment cycle was reported by 39% and 68% of the patients, respectively. The comparable figures for acute and delayed vomiting were 12% and 23%. Approximately one-third of the patients indicated that CINV had a substantial impact on their daily lives. Patients receiving treatment with moderately emetogenic chemotherapy containing anthracycline, reported more acute nausea than patients receiving highly emetogenic chemotherapy. Acute vomiting was associated significantly with change in (i.e., additional) antiemetic treatment. Delayed CINV did not influence antiemetic treatment. CONCLUSION: In daily clinical practice, acute CINV, but not delayed CINV, results in changes in antiemetic treatment. In view of the effects of not only acute but also delayed CINV on daily life, more attention should be paid to adjustment of anti-emetic treatment to cover CINV complaints later during the chemotherapy cycle.

UR - http://www.scopus.com/inward/record.url?scp=84868276853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868276853&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84868276853

VL - 147

SP - 168

EP - 176

JO - Pharmaceutisch Weekblad

JF - Pharmaceutisch Weekblad

SN - 0031-6911

IS - 42

ER -